LOVE LIBRARY

&

Buy propecia finasteride 1mg

CMS, Office of Strategic Operations buy propecia finasteride 1mg propecia canada reddit and Regulatory Affairs, Division of Regulations Development, Attention. Document Identifier/OMB Control Number. __, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, buy propecia finasteride 1mg you may make your request using one of following.

1. Access CMS' website address at website address at https://www.cms.gov/​Regulations-and-Guidance/​Legislation/​PaperworkReductionActof1995/​PRA-Listing.html. Start Further Info William N buy propecia finasteride 1mg. Parham at (410) 786-4669.

End Further Info End Preamble Start Supplemental Information Contents This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection's supporting statement buy propecia finasteride 1mg and associated materials (see ADDRESSES). CMS-10148 HIPAA Administrative Simplification (Non-Privacy/Security) Complaint Form CMS-10784 The Home Health Care CAHPS® Survey (HHCAHPS) Mode Experiment Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor.

The term “collection of information” buy propecia finasteride 1mg is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice buy propecia finasteride 1mg.

Information Collection 1. Type of Information Collection Request. Extension of buy propecia finasteride 1mg a currently approved collection. Title of Information Collection.

HIPAA Administrative Simplification (Non-Privacy/Security) Complaint Form. Use. The Secretary of Health and Human Services (HHS), hereafter known as “The Secretary,” codified 45 CFR parts 160 and 164 Administrative Simplification provisions that apply to the enforcement of the Health Insurance Portability and Accountability Act of 1996 Public Law 104-191 (HIPAA). The provisions address rules relating to the investigation of non-compliance of the HIPAA Administrative Simplification code sets, unique identifiers, operating rules, and transactions.

45 CFR 160.306, Complaints to the Secretary, provides for investigations of covered entities by the Secretary. Further, it outlines the procedures and requirements for filing a complaint against a covered entity. Anyone can file a complaint if he or she suspects a potential violation. Persons believing that a covered entity is not utilizing the adopted Administrative Simplification provisions of HIPAA are voluntarily requested to file a complaint with CMS via the Administrative Simplification Enforcement and Testing Tool (ASETT) online system, by mail, or by sending an email to the HIPAA mailbox at hipaacomplaint@cms.hhs.gov.

Information provided on the standard form will be used during the investigation process to validate non-compliance of HIPAA Administrative Simplification provisions. This standard form collects identifying and contact information of the complainant, as well as the identifying and contact information of the filed against entity (FAE). This information enables CMS to respond to the complainant and gather more information if necessary, and to contact the FAE to discuss the complaint and CMS' findings. Form Number.

CMS-10148 (OMB control number. 0938-0948). Frequency. Occasionally.

Affected Public. Private sector, Business or Not-for-profit institutions, State, Local, or Tribal Governments, Federal Government, Not-for-profits institutions. Number of Respondents. 21.

Total Annual Responses. 21. Total Annual Hours. 12.

(For policy questions regarding this collection contact Kevin Stewart at 410-786-6149). 2. Type of Information Collection Request. New collection (Request for a new OMB control).

Title of Information Collection. The Home Health Care CAHPS® Survey (HHCAHPS) Mode Experiment. Use. The reporting of quality data by HHAs is mandated by Section 1895(b)(3)(B)(v)(II) of the Social Security Act (“the Act”).

This statute requires that “each home health agency shall submit to the Secretary such data that the Secretary determines are appropriate for the measurement of health care quality. Such data shall be submitted in a form and manner, and at a time, specified by the Secretary for purposes of this clause.” HHCAHPS data are mandated in the Medicare regulations at 42 CFR 484.250(a), which requires HHAs to submit HHCAHPS data to meet the quality reporting requirements of section 1895(b)(3)(B)(v) of the Act. This collection of information is necessary to be able to test updates to the HHCAHPS survey and administration protocols. CMS proposes to conduct a mode experiment with the main goal of testing the effects of a web-based mode on response rates and scores as an addition to the three currently approved modes (OMB Control Number.

0938-1370). The addition of a web mode will give HHAs an alternative or an addition to the use of mail and telephone modes. CMS is also interested in testing a revised, shorter version of the HHCAHPS survey, based on feedback from patients and stakeholders. The data collected from the HHCAHPS Survey mode experiment will be used for the following purposes.

Test the shortened survey instrument, including several new items. Compare survey responses across the four proposed modes to determine if adjustments are needed to ensure that data collection mode does not influence results. And Determine if and by how much patient characteristics affect the patients' rating of the care they receive Start Printed Page 42843and adjust results based on those factors. The mode experiment is designed to examine the effects of the shortened survey on response rates and scores and to provide precise adjustment estimates for survey items and composites on the shortened survey instrument.

Information from this mode experiment will help CMS determine whether an additional mode of administration (i.e., Web data collection) should be included and a shortened survey instrument should be used in the current national implementation of the HHCAHPS Survey. Form Number. CMS-10784 (OMB control number. 0938-New).

Frequency. Annually. Affected Public. Individuals or Households.

Best site to buy propecia online

Propecia
Dutas
Proscar
Finast
Can women take
You need consultation
No
Ask your Doctor
Ask your Doctor
Best way to use
Headache
Flushing
Back pain
Abnormal vision
Effect on blood pressure
1mg 240 tablet $155.95
$
5mg 90 tablet $103.95
$

For millions of people with epilepsy and movement disorders such as Parkinson's disease, electrical stimulation of the cheap generic propecia brain already is best site to buy propecia online widening treatment possibilities. In the future, electrical stimulation may help people with psychiatric illness and direct brain injuries, such as stroke.However, studying how brain networks interact with each other is best site to buy propecia online complicated. Brain networks can be explored by delivering brief pulses of electrical current in one area of a patient's brain while measuring voltage responses in other areas.

In principle, one should be able to best site to buy propecia online infer the structure of brain networks from these data. However, with real-world data, the problem is difficult because the recorded signals are complex, and a limited amount of measurements can be made.To make the problem manageable, Mayo Clinic researchers developed a set of paradigms, or viewpoints, that simplify comparisons between effects of electrical stimulation on the brain. Because a mathematical technique to characterize how assemblies of inputs converge in human brain regions did not exist in the scientific literature, the Mayo team collaborated with an international expert in artificial intelligence (AI) algorithms to develop a new type of algorithm called "basis profile curve identification."In a study published in PLOS Computational Biology, a patient with a brain tumor underwent placement of an electrocorticographic electrode array to locate seizures and best site to buy propecia online map brain function before a tumor was removed.

Every electrode interaction resulted in hundreds to thousands of time points to be studied using the new algorithm."Our findings show that this new type of algorithm may help us understand which brain regions directly interact with one another, which in turn may help guide placement of electrodes for stimulating devices to treat network brain diseases," says Kai Miller, M.D., Ph.D., a Mayo Clinic neurosurgeon and first author of the study. "As new technology emerges, this type of algorithm may help us to better treat patients with epilepsy, movement disorders like Parkinson's disease, and psychiatric illnesses like obsessive compulsive disorder and depression.""Neurologic data best site to buy propecia online to date is perhaps the most challenging and exciting data to model for AI researchers," says Klaus-Robert Mueller, Ph.D., study co-author and member of the Google Research Brain Team. Dr.

Mueller is co-director of the Berlin Institute for the Foundations of Learning and Data and director of the Machine Learning Group -- both at Technical University of Berlin.In the study, the authors best site to buy propecia online provide a downloadable code package so others may explore the technique. "Sharing the developed code is a core part of our efforts to help reproducibility of research," says Dora Hermes, Ph.D., a Mayo Clinic biomedical engineer and senior author.This research was supported by National Institutes of Health's National Center for Advancing Translational Science Clinical and Translational Science Award, National Institute of Mental Health Collaborative Research in Computational Neuroscience, and the Federal Ministry of Education and Research. Story Source best site to buy propecia online.

Materials provided by Mayo Clinic. Original written by Susan Barber Lindquist best site to buy propecia online. Note.

Content may be edited for style and length.For most, the relentless snapping of camera shutters is an all too best site to buy propecia online familiar sound associated with trips and vacations. When venturing to a new place, travelers everywhere are constantly on the search for that picture-perfect, Instagram worthy shot. Persevering through many takes, amateur photographers fight blurred backgrounds, closed eyes, and photo-bombing passersby all in search of that ever-elusive perfect picture.As it turns out, neuroscientists are very similar to travelers in this regard, constantly developing and practicing new ways to take perfect, crystal-clear images best site to buy propecia online.

But instead of picturesque natural backdrops or striking city scenes, neuroscientists are interested in detailed snapshots of brain cells and their small-scale structures.The Yasuda Lab at MPFI is incredibly well versed in small-scale structures of the brain, focused on studying the dynamic changes to tiny synaptic compartments called dendritic spines. Robust changes in spine structure known as structural plasticity, allow synapses to robustly modulate their best site to buy propecia online connection strength. By doing so, cells in the brain can actively strengthen important connections and weaken those that are less needed.

This process is thought to best site to buy propecia online underlie how we learn and remember. But revealing the fine structures of spines in detail during such a dynamic process is best site to buy propecia online a difficult undertaking. Until recently, imaging methodologies lacked the capabilities to do so.In a recent publication in The Journal of Neuroscience, researchers in the Yasuda Lab have developed a powerful new imaging strategy capable of visualizing the fine, uastructural changes to dendritic spines during structural plasticity.

By modifying best site to buy propecia online and building off an established imaging technique known as correlative light and electron microscopy (CLEM), MPFI scientists have harnessed the best that both imaging modalities can provide."Dendritic spines are such small-scale neuronal compartments, that it's difficult to get an accurate picture of what's actually occurring in terms of structural changes using traditional imaging methods," explains Dr. Ryohei Yasuda, Scientific Director at MPFI. "Using more standard optical techniques like 2-photon microscopy, best site to buy propecia online dendritic spines look like smooth spheres.

In actuality, we know from using more powerful imaging methods, like electron microscopy, that the actual size and shape of spines are far more complex. So, we were interested in learning what changes occur during the various stages of structural plasticity, at a resolution where we could take a deeper look at the spine's complexity."The MPFI team first induced structural plasticity in single dendritic spines using 2-photon optical microscopy and best site to buy propecia online glutamate uncaging. The induced spine was then fixed in time at one of three distinct timepoints, representing the major stages of structural plasticity.

In close collaboration with MPFI's Electron Microscopy (EM) Core, brain best site to buy propecia online tissue samples containing the stimulated spines were cut into ua-thin sections using a specialized device called ATUMtome. These sections were then re-imaged using the extreme resolving power of the Electron Microscope to reveal the uastructural details and reconstruct accurate pictures of the spine's complex topography."When we started this project, our goal was to see if it was even possible to collect spines at various stages of structural plasticity, successfully relocate them, and resolve their uastructure using EM," describes Ye Sun, Ph.D., former Graduate Student in the Yasuda Lab and first author of the publication. "Single, spine-specific forms of structural plasticity have never best site to buy propecia online been imaged in this way before.

Dr. Naomi kamasawa, Head of MPFI's EM Core, was instrumental in helping to establish and optimize our EM workflow for the project."Examining the reconstructed spine images, the MPFI team noticed best site to buy propecia online unique changes to a protein-rich region of dendritic spines, called the postsynaptic density (PSD). This region is critically important for the spine, implicated in regulating synaptic strength and plasticity.

MPFI researchers found that compared to control spines, best site to buy propecia online the area and size of the PSD region was significantly greater in spines that underwent structural plasticity. PSD growth in these spines occurred on a slower timescale, needing hours to reach its maximal change. Interestingly while growth was on a slower scale, PSD structure in stimulated spines reorganized best site to buy propecia online at a rapid pace.

After the induction of structural plasticity, PSD complexity immediately increased, dramatically transforming in shape and structural features."Our imaging strategy synergizes the best of both optical and EM microscopies, allowing us to study spine structural changes never before seen in nanoscale resolution," notes Dr. Yasuda. "For the future, our lab is interested in using this new protocol in combination with advanced molecular techniques, such as SLENDR, to study individual protein dynamics in tandem with finely detailed structural changes during spine structural plasticity..

For millions of people with epilepsy and movement buy propecia finasteride 1mg disorders such as Parkinson's disease, cheap generic propecia electrical stimulation of the brain already is widening treatment possibilities. In the buy propecia finasteride 1mg future, electrical stimulation may help people with psychiatric illness and direct brain injuries, such as stroke.However, studying how brain networks interact with each other is complicated. Brain networks can be explored by delivering brief pulses of electrical current in one area of a patient's brain while measuring voltage responses in other areas. In principle, one should be able to infer the structure of brain networks buy propecia finasteride 1mg from these data.

However, with real-world data, the problem is difficult because the recorded signals are complex, and a limited amount of measurements can be made.To make the problem manageable, Mayo Clinic researchers developed a set of paradigms, or viewpoints, that simplify comparisons between effects of electrical stimulation on the brain. Because a mathematical technique to characterize how assemblies of inputs converge in human brain regions did not exist in the scientific literature, the Mayo team collaborated with an international expert in artificial intelligence (AI) algorithms to develop a new type of algorithm called "basis profile curve identification."In a study published in PLOS Computational Biology, a patient with a brain tumor underwent placement of buy propecia finasteride 1mg an electrocorticographic electrode array to locate seizures and map brain function before a tumor was removed. Every electrode interaction resulted in hundreds to thousands of time points to be studied using the new algorithm."Our findings show that this new type of algorithm may help us understand which brain regions directly interact with one another, which in turn may help guide placement of electrodes for stimulating devices to treat network brain diseases," says Kai Miller, M.D., Ph.D., a Mayo Clinic neurosurgeon and first author of the study. "As new technology emerges, this type of algorithm may help us to better treat patients with epilepsy, movement disorders like Parkinson's disease, and psychiatric illnesses like obsessive compulsive buy propecia finasteride 1mg disorder and depression.""Neurologic data to date is perhaps the most challenging and exciting data to model for AI researchers," says Klaus-Robert Mueller, Ph.D., study co-author and member of the Google Research Brain Team.

Dr. Mueller is co-director of the Berlin Institute for the Foundations of Learning and Data and director of the Machine Learning Group -- both buy propecia finasteride 1mg at Technical University of Berlin.In the study, the authors provide a downloadable code package so others may explore the technique. "Sharing the developed code is a core part of our efforts to help reproducibility of research," says Dora Hermes, Ph.D., a Mayo Clinic biomedical engineer and senior author.This research was supported by National Institutes of Health's National Center for Advancing Translational Science Clinical and Translational Science Award, National Institute of Mental Health Collaborative Research in Computational Neuroscience, and the Federal Ministry of Education and Research. Story Source buy propecia finasteride 1mg.

Materials provided by Mayo Clinic. Original written by Susan buy propecia finasteride 1mg Barber Lindquist. Note. Content may be edited for buy propecia finasteride 1mg style and length.For most, the relentless snapping of camera shutters is an all too familiar sound associated with trips and vacations.

When venturing to a new place, travelers everywhere are constantly on the search for that picture-perfect, Instagram worthy shot. Persevering through many takes, amateur photographers fight blurred backgrounds, closed eyes, and photo-bombing passersby all in search of that buy propecia finasteride 1mg ever-elusive perfect picture.As it turns out, neuroscientists are very similar to travelers in this regard, constantly developing and practicing new ways to take perfect, crystal-clear images. But instead of picturesque natural backdrops or striking city scenes, neuroscientists are interested in detailed snapshots of brain cells and their small-scale structures.The Yasuda Lab at MPFI is incredibly well versed in small-scale structures of the brain, focused on studying the dynamic changes to tiny synaptic compartments called dendritic spines. Robust changes in spine buy propecia finasteride 1mg structure known as structural plasticity, allow synapses to robustly modulate their connection strength.

By doing so, cells in the brain can actively strengthen important connections and weaken those that are less needed. This process is thought buy propecia finasteride 1mg to underlie how we learn and remember. But revealing the fine structures of spines in detail during such a dynamic process is a difficult undertaking buy propecia finasteride 1mg. Until recently, imaging methodologies lacked the capabilities to do so.In a recent publication in The Journal of Neuroscience, researchers in the Yasuda Lab have developed a powerful new imaging strategy capable of visualizing the fine, uastructural changes to dendritic spines during structural plasticity.

By modifying and building off an established imaging technique known as correlative light and electron microscopy (CLEM), MPFI scientists have harnessed the best that both imaging modalities can provide."Dendritic spines are such small-scale neuronal compartments, that it's difficult to get an accurate picture of what's actually occurring in terms of structural changes buy propecia finasteride 1mg using traditional imaging methods," explains Dr. Ryohei Yasuda, Scientific Director at MPFI. "Using more standard optical buy propecia finasteride 1mg techniques like 2-photon microscopy, dendritic spines look like smooth spheres. In actuality, we know from using more powerful imaging methods, like electron microscopy, that the actual size and shape of spines are far more complex.

So, we were interested in learning what changes occur during the various stages of structural plasticity, at a resolution where we could take a buy propecia finasteride 1mg deeper look at the spine's complexity."The MPFI team first induced structural plasticity in single dendritic spines using 2-photon optical microscopy and glutamate uncaging. The induced spine was then fixed in time at one of three distinct timepoints, representing the major stages of structural plasticity. In close collaboration with MPFI's Electron Microscopy (EM) Core, brain tissue buy propecia finasteride 1mg samples containing the stimulated spines were cut into ua-thin sections using a specialized device called ATUMtome. These sections were then re-imaged using the extreme resolving power of the Electron Microscope to reveal the uastructural details and reconstruct accurate pictures of the spine's complex topography."When we started this project, our goal was to see if it was even possible to collect spines at various stages of structural plasticity, successfully relocate them, and resolve their uastructure using EM," describes Ye Sun, Ph.D., former Graduate Student in the Yasuda Lab and first author of the publication.

"Single, spine-specific forms buy propecia finasteride 1mg of structural plasticity have never been imaged in this way before. Dr. Naomi kamasawa, Head of MPFI's EM Core, was instrumental in helping to establish and optimize our EM workflow for the project."Examining the reconstructed spine buy propecia finasteride 1mg images, the MPFI team noticed unique changes to a protein-rich region of dendritic spines, called the postsynaptic density (PSD). This region is critically important for the spine, implicated in regulating synaptic strength and plasticity.

MPFI researchers found that compared to control spines, the area and size of the PSD region was significantly buy propecia finasteride 1mg greater in spines that underwent structural plasticity. PSD growth in these spines occurred on a slower timescale, needing hours to reach its maximal change. Interestingly while growth was on a slower scale, PSD structure in stimulated spines reorganized at buy propecia finasteride 1mg a rapid pace. After the induction of structural plasticity, PSD complexity immediately increased, dramatically transforming in shape and structural features."Our imaging strategy synergizes the best of both optical and EM microscopies, allowing us to study spine structural changes never before seen in nanoscale resolution," notes Dr.

Yasuda. "For the future, our lab is interested in using this new protocol in combination with advanced molecular techniques, such as SLENDR, to study individual protein dynamics in tandem with finely detailed structural changes during spine structural plasticity..

What side effects may I notice from Propecia?

Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome):

  • breast enlargement or tenderness
  • skin rash
  • sexual difficulties (less sexual desire or ability to get an erection)
  • small amount of semen released during sex

This list may not describe all possible side effects.

How safe is propecia

The Henry Buy cialis in montreal J how safe is propecia. Kaiser Family how safe is propecia Foundation Headquarters. 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400 Washington Offices and Barbara Jordan Conference Center.

1330 G Street, NW, Washington, how safe is propecia DC 20005 | Phone 202-347-5270 www.kff.org | Email Alerts. Kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California..

The Henry buy propecia finasteride 1mg J. Kaiser Family Foundation Headquarters buy propecia finasteride 1mg. 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400 Washington Offices and Barbara Jordan Conference Center. 1330 G Street, buy propecia finasteride 1mg NW, Washington, DC 20005 | Phone 202-347-5270 www.kff.org | Email Alerts. Kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California..

Propecia cheveux

A 33-year old man was found to have a second hair loss some four-and-a-half months after he was diagnosed with his propecia cheveux first, from which he recovered. The man, who showed no symptoms, was diagnosed when he returned to Hong Kong after a trip to Spain.I am a virologist with expertise in hair losses and enteropropeciaes, and I’ve been curious about res since the beginning of the propecia. Because people infected with hair loss can often test positive for propecia cheveux the propecia for weeks to months, likely due to the sensitivity of the test and leftover RNA fragments, the only way to really answer the question of re is by sequencing the viral genome at the time of each and looking for differences in the genetic code.There is no published peer-review report on this man – only a press release from the University of Hong Kong – although reports say the work will be published in the journal Clinical Infectious Diseases. Here I address some questions raised by the current news reports.Why wasn’t the man immune to re?. Immunity to endemic hair losses propecia cheveux – those that cause symptoms of the common cold – is relatively short-lived, with res occurring even within the same season.

So it isn’t completely surprising that re with hair loss, the propecia that causes hair loss treatment, might be possible.Immunity is complex and involves multiple mechanisms in the body. That includes the generation of antibodies – through what’s known as the adaptive immune response – and through the actions of T-cells, which can help to educate the immune propecia cheveux system and to specifically eliminate propecia-infected cells. However, researchers around the world are still learning about immunity to this propecia and so can’t say for sure, based on this one case, whether re will be a cause for broad concern.[Get the best of The Conversation, every weekend. Sign up for our weekly newsletter.]How different is the second strain propecia cheveux that infected the Hong Kong man?. “Strain” has a particular definition when referring to propeciaes.

Often a propecia cheveux different “strain” is a propecia that behaves differently in some way. The hair loss that infected this man in Europe is likely not a new strain.A STAT News article reports that the genetic make up of the sequenced propecia from the patient’s second had 24 nucleotides – building blocks of the propecia’s RNA genome – that differed from the hair loss isolate that infected him the first time.hair loss has a genome that is made up of about 30,000 nucleotides, so the propecia from the man’s second was roughly 0.08% different than the original in genome sequence. That shows that the propecia that caused the second was new. Not a recurrence of the first propecia.The man was asymptomatic – propecia cheveux what does that mean?. The man wasn’t suffering any of the hallmark hair loss treatment symptoms which might mean he had some degree of protective immunity to the second because he didn’t seem sick.

But this is difficult to propecia cheveux prove.I see three possible explanations. The first is that the immunity he gained from the first protected him and allowed for a mild second . Another possibility is that the was mild because he was presymptomatic, and went on propecia cheveux to develop symptoms in the coming days. Finally, sometimes s with hair loss are asymptomatic – at the moment it is difficult to determine whether this was due to the differences in the propecia or in the host.What can we say about re based on this one case?. Only that it seems to be possible after enough propecia cheveux time has elapsed.

We do not know how likely or often it is to occur.Should people who have recovered from hair loss treatment still wear a mask?. As we are still learning about how humans develop immunity to hair loss after propecia cheveux , my recommendation is for continued masking, hand hygiene and distancing practices, even after recovery from hair loss treatment, to protect against the potential for re.Megan Culler Freeman is a Pediatric Infectious Diseases Fellow at the University of Pittsburgh. This article originally appeared on The Conversation and is republished under a Creative Commons license. Read the original here..

A 33-year old man was found to have a second buy propecia finasteride 1mg hair loss some four-and-a-half months after he was diagnosed with his first, from which he recovered. The man, who showed no symptoms, was diagnosed when he returned to Hong Kong after a trip to Spain.I am a virologist with expertise in hair losses and enteropropeciaes, and I’ve been curious about res since the beginning of the propecia. Because people infected with hair loss can often test positive for the propecia for weeks to months, likely due buy propecia finasteride 1mg to the sensitivity of the test and leftover RNA fragments, the only way to really answer the question of re is by sequencing the viral genome at the time of each and looking for differences in the genetic code.There is no published peer-review report on this man – only a press release from the University of Hong Kong – although reports say the work will be published in the journal Clinical Infectious Diseases.

Here I address some questions raised by the current news reports.Why wasn’t the man immune to re?. Immunity to endemic hair losses – those that cause symptoms of the buy propecia finasteride 1mg common cold – is relatively short-lived, with res occurring even within the same season. So it isn’t completely surprising that re with hair loss, the propecia that causes hair loss treatment, might be possible.Immunity is complex and involves multiple mechanisms in the body.

That includes the buy propecia finasteride 1mg generation of antibodies – through what’s known as the adaptive immune response – and through the actions of T-cells, which can help to educate the immune system and to specifically eliminate propecia-infected cells. However, researchers around the world are still learning about immunity to this propecia and so can’t say for sure, based on this one case, whether re will be a cause for broad concern.[Get the best of The Conversation, every weekend. Sign up buy propecia finasteride 1mg for our weekly newsletter.]How different is the second strain that infected the Hong Kong man?.

“Strain” has a particular definition when referring to propeciaes. Often a different “strain” is a propecia that behaves differently in some buy propecia finasteride 1mg way. The hair loss that infected this man in Europe is likely not a new strain.A STAT News article reports that the genetic make up of the sequenced propecia from the patient’s second had 24 nucleotides – building blocks of the propecia’s RNA genome – that differed from the hair loss isolate that infected him the first time.hair loss has a genome that is made up of about 30,000 nucleotides, so the propecia from the man’s second was roughly 0.08% different than the original in genome sequence.

That shows that the propecia that caused the second was new. Not a recurrence buy propecia finasteride 1mg of the first propecia.The man was asymptomatic – what does that mean?. The man wasn’t suffering any of the hallmark hair loss treatment symptoms which might mean he had some degree of protective immunity to the second because he didn’t seem sick.

But this is difficult to prove.I see buy propecia finasteride 1mg three possible explanations. The first is that the immunity he gained from the first protected him and allowed for a mild second . Another possibility is that the was mild because he was presymptomatic, and went on to develop symptoms in the coming buy propecia finasteride 1mg days.

Finally, sometimes s with hair loss are asymptomatic – at the moment it is difficult to determine whether this was due to the differences in the propecia or in the host.What can we say about re based on this one case?. Only that it seems to be possible after enough time has buy propecia finasteride 1mg elapsed. We do not know how likely or often it is to occur.Should people who have recovered from hair loss treatment still wear a mask?.

As we are still learning about how buy propecia finasteride 1mg humans develop immunity to hair loss after , my recommendation is for continued masking, hand hygiene and distancing practices, even after recovery from hair loss treatment, to protect against the potential for re.Megan Culler Freeman is a Pediatric Infectious Diseases Fellow at the University of Pittsburgh. This article originally appeared on The Conversation and is republished under a Creative Commons license. Read the original here..

Where can i buy propecia in canada

At that time, where can i buy propecia in canada this drug benefit was "carved into" the Medicaid managed http://ernieandjesse.com/?p=4785 care benefit package. Before that date, people enrolled in a Medicaid managed care plan obtained all of their health care through the plan, but used their regular Medicaid card to access any drug available on the state formulary on a "fee for service" basis without needing to utilize a restricted pharmacy network or comply with managed care plan rules. COMING IN April 2021 - In the NYS Budget enacted in April 2020, the pharmacy benefit was "carved out" of "mainstream" Medicaid managed care plans.

That means that members of managed care plans will access their drugs outside their plan, unlike the rest of where can i buy propecia in canada their medical care, which is accessed from in-network providers. How Prescription Drugs are Obtained through Managed Care plans No - Until April 2020 HOW DO MANAGED CARE PLANS DEFINE THE PHARMACY BENEFIT FOR CONSUMERS?. The Medicaid pharmacy benefit includes all FDA approved prescription drugs, as well as some over-the-counter drugs and medical supplies.

Under Medicaid where can i buy propecia in canada managed care. Plan formularies will be comparable to but not the same as the Medicaid formulary. Managed care plans are required to have drug formularies that are “comparable” to the Medicaid fee for service formulary.

Plan formularies where can i buy propecia in canada do not have to include all drugs covered listed on the fee for service formulary, but they must include generic or therapeutic equivalents of all Medicaid covered drugs. The Pharmacy Benefit will vary by plan. Each plan will have its own formulary and drug coverage policies like prior authorization and step therapy.

Pharmacy networks can also where can i buy propecia in canada differ from plan to plan. Prescriber Prevails applies in certain drug classes. Prescriber prevails applys to medically necessary precription drugs in the following classes.

atypical antipsychotics, anti-depressants, anti-retrovirals, anti-rejection, seizure, epilepsy, endocrine, where can i buy propecia in canada hemotologic and immunologic therapeutics. Prescribers will need to demonstrate reasonable profession judgment and supply plans witht requested information and/or clinical documentation. Pharmacy Benefit Information Website -- http://mmcdruginformation.nysdoh.suny.edu/-- This website provides very helpful information on a plan by plan basis regarding pharmacy networks and drug formularies.

The Department of Health plans to build capacity for interactive where can i buy propecia in canada searches allowing for comparison of coverage across plans in the near future. Standardized Prior Autorization (PA) Form -- The Department of Health worked with managed care plans, provider organizations and other state agencies to develop a standard prior authorization form for the pharmacy benefit in Medicaid managed care. The form will be posted on the Pharmacy Information Website in July of 2013.

Mail Order Drugs -- Medicaid managed care members can obtain mail order/specialty drugs at any retail network pharmacy, as long as where can i buy propecia in canada that retail network pharmacy agrees to a price that is comparable to the mail order/specialty pharmacy price. CAN CONSUMERS SWITCH PLANS IN ORDER TO GAIN ACCESS TO DRUGS?. Changing plans is often an effective strategy for consumers eligible for both Medicaid and Medicare (dual eligibles) who receive their pharmacy service through Medicare Part D, because dual eligibles are allowed to switch plans at any time.

Medicaid consumers will where can i buy propecia in canada have this option only in the limited circumstances during the first year of enrollment in managed care. Medicaid managed care enrollees can only leave and join another plan within the first 90 days of joining a health plan. After the 90 days has expired, enrollees are “locked in” to the plan for the rest of the year.

Consumers can switch plans during the where can i buy propecia in canada “lock in” period only for good cause. The pharmacy benefit changes are not considered good cause. After the first 12 months of enrollment, Medicaid managed care enrollees can switch plans at any time.

STEPS CONSUMERS CAN TAKE WHEN A MANAGED CARE PLAM DENIES ACCESS TO A NECESSARY DRUG As a first step, consumers should try to work with their providers to satisfy plan requirements for prior where can i buy propecia in canada authorization or step therapy or any other utilization control requirements. If the plan still denies access, consumers can pursue review processes specific to managed care while at the same time pursuing a fair hearing. All plans are required to maintain an internal and external review process for complaints and appeals of service denials.

Some plans may develop special where can i buy propecia in canada procedures for drug denials. Information on these procedures should be provided in member handbooks. Beginning April 1, 2018, Medicaid managed care enrollees whose plan denies prior approval of a prescription drug, or discontinues a drug that had been approved, will receive an Initial Adverse Determination notice from the plan - See Model Denial IAD Notice and IAD Notice to Reduce, Suspend or Stop Services The enrollee must first request an internal Plan Appeal and wait for the Plan's decision.

An adverse decision is called a 'FInal Adverse Determination" or FAD where can i buy propecia in canada. See model Denial FAD Notice and FAD Notice to Reduce, Suspend or Stop Services. The enroll has the right to request a fair hearing to appeal an FAD.

The enrollee may only request a fair hearing BEFORE receiving the FAD if the plan fails where can i buy propecia in canada to send the FAD in the required time limit, which is 30 calendar days in standard appeals, and 72 hours in expedited appeals. The plan may extend the time to decide both standard and expedited appeals by up to 14 days if more information is needed and it is in the enrollee's interest. AID CONTINUING -- If an enrollee requests a Plan Appeal and then a fair hearing because access to a drug has been reduced or terminated, the enrollee has the right to aid continuing (continued access to the drug in question) while waiting for the Plan Appeal and then the fair hearing.

The enrollee must request the Plan Appeal and then the Fair where can i buy propecia in canada Hearing before the effective date of the IAD and FAD notices, which is a very short time - only 10 days including mailing time. See more about the changes in Managed Care appeals here. Even though that article is focused on Managed Long Term Care, the new appeals requirements also apply to Mainstream Medicaid managed care.

Enrollees who are in the first 90 days of enrollment, or past the first 12 months of enrollment also have the option of switching plans to improve access to their where can i buy propecia in canada medications. Consumers who experience problems with access to prescription drugs should always file a complaint with the State Department of Health’s Managed Care Hotline, number listed below. ACCESSING MEDICAID'S PHARMACY BENEFIT IN FEE FOR SERVICE MEDICAID For those Medicaid recipients who are not yet in a Medicaid Managed Care program, and who do not have Medicare Part D, the Medicaid Pharmacy program covers most of their prescription drugs and select non-prescription drugs and medical supplies for Family Health Plus enrollees.

Certain drugs/drug categories require the prescribers to where can i buy propecia in canada obtain prior authorization. These include brand name drugs that have a generic alternative under New York's mandatory generic drug program or prescribed drugs that are not on New York's preferred drug list. The full Medicaid formulary can be searched on the eMedNY website.

Even in fee for service Medicaid, prescribers must obtain prior authorization before prescribing non-preferred drugs unless otherwise indicated. Prior authorization is required for original prescriptions, not refills. A prior authorization is effective for the original dispensing and up to five refills of that prescription within the next six months.

Click here for more information on NY's prior authorization process. The New York State Board of Pharmacy publishes an annual list of the 150 most frequently prescribed drugs, in the most common quantities. The State Department of Health collects retail price information on these drugs from pharmacies that participate in the Medicaid program.

Click here to search for a specific drug from the most frequently prescribed drug list and this site can also provide you with the locations of pharmacies that provide this drug as well as their costs. Click here to view New York State Medicaid’s Pharmacy Provider Manual. WHO YOU CAN CALL FOR HELP Community Health Advocates Hotline.

1-888-614-5400 NY State Department of Health's Managed Care Hotline. 1-800-206-8125 (Mon. - Fri.

Before that date, people enrolled in a Medicaid managed informative post care plan obtained all of their health care through the plan, but used their regular Medicaid card to access any drug available on the state formulary on a "fee for service" basis without needing to utilize a restricted pharmacy network or comply with managed buy propecia finasteride 1mg care plan rules. COMING IN April 2021 - In the NYS Budget enacted in April 2020, the pharmacy benefit was "carved out" of "mainstream" Medicaid managed care plans. That means that members of managed care plans will access their drugs outside their plan, unlike the rest of their medical care, which is accessed from in-network providers. How Prescription Drugs are Obtained through Managed Care plans No - Until April 2020 HOW DO MANAGED CARE buy propecia finasteride 1mg PLANS DEFINE THE PHARMACY BENEFIT FOR CONSUMERS?. The Medicaid pharmacy benefit includes all FDA approved prescription drugs, as well as some over-the-counter drugs and medical supplies.

Under Medicaid managed care. Plan formularies will be comparable to but not the same as the Medicaid formulary buy propecia finasteride 1mg. Managed care plans are required to have drug formularies that are “comparable” to the Medicaid fee for service formulary. Plan formularies do not have to include all drugs covered listed on the fee for service formulary, but they must include generic or therapeutic equivalents of all Medicaid covered drugs. The Pharmacy buy propecia finasteride 1mg Benefit will vary by plan.

Each plan will have its own formulary and drug coverage policies like prior authorization and step therapy. Pharmacy networks can also differ from plan to plan. Prescriber Prevails applies in certain drug classes buy propecia finasteride 1mg. Prescriber prevails applys to medically necessary precription drugs in the following classes. atypical antipsychotics, anti-depressants, anti-retrovirals, anti-rejection, seizure, epilepsy, endocrine, hemotologic and immunologic therapeutics.

Prescribers will need to demonstrate reasonable profession judgment and supply plans witht requested information and/or clinical documentation buy propecia finasteride 1mg. Pharmacy Benefit Information Website -- http://mmcdruginformation.nysdoh.suny.edu/-- This website provides very helpful information on a plan by plan basis regarding pharmacy networks and drug formularies. The Department of Health plans to build capacity for interactive searches allowing for comparison of coverage across plans in the near future. Standardized Prior buy propecia finasteride 1mg Autorization (PA) Form -- The Department of Health worked with managed care plans, provider organizations and other state agencies to develop a standard prior authorization form for the pharmacy benefit in Medicaid managed care. The form will be posted on the Pharmacy Information Website in July of 2013.

Mail Order Drugs -- Medicaid managed care members can obtain mail order/specialty drugs at any retail network pharmacy, as long as that retail network pharmacy agrees to a price that is comparable to the mail order/specialty pharmacy price. CAN CONSUMERS SWITCH PLANS IN ORDER TO GAIN ACCESS TO DRUGS? buy propecia finasteride 1mg. Changing plans is often an effective strategy for consumers eligible for both Medicaid and Medicare (dual eligibles) who receive their pharmacy service through Medicare Part D, because dual eligibles are allowed to switch plans at any time. Medicaid consumers will have this option only in the limited circumstances during the first year of enrollment in managed care. Medicaid managed care enrollees can only leave and join another plan within the first 90 buy propecia finasteride 1mg days of joining a health plan.

After the 90 days has expired, enrollees are “locked in” to the plan for the rest of the year. Consumers can switch plans during the “lock in” period only for good cause. The pharmacy benefit changes are not considered good buy propecia finasteride 1mg cause. After the first 12 months of enrollment, Medicaid managed care enrollees can switch plans at any time. STEPS CONSUMERS CAN TAKE WHEN A MANAGED CARE PLAM DENIES ACCESS TO A NECESSARY DRUG As a first step, consumers should try to work with their providers to satisfy plan requirements for prior authorization or step therapy or any other utilization control requirements.

If buy propecia finasteride 1mg the plan still denies access, consumers can pursue review processes specific to managed care while at the same time pursuing a fair hearing. All purchase propecia canada plans are required to maintain an internal and external review process for complaints and appeals of service denials. Some plans may develop special procedures for drug denials. Information on these procedures should be provided in member buy propecia finasteride 1mg handbooks. Beginning April 1, 2018, Medicaid managed care enrollees whose plan denies prior approval of a prescription drug, or discontinues a drug that had been approved, will receive an Initial Adverse Determination notice from the plan - See Model Denial IAD Notice and IAD Notice to Reduce, Suspend or Stop Services The enrollee must first request an internal Plan Appeal and wait for the Plan's decision.

An adverse decision is called a 'FInal Adverse Determination" or FAD. See model Denial FAD Notice and FAD Notice to Reduce, Suspend or buy propecia finasteride 1mg Stop Services. The enroll has the right to request a fair hearing to appeal an FAD. The enrollee may only request a fair hearing BEFORE receiving the FAD if the plan fails to send the FAD in the required time limit, which is 30 calendar days in standard appeals, and 72 hours in expedited appeals. The buy propecia finasteride 1mg plan may extend the time to decide both standard and expedited appeals by up to 14 days if more information is needed and it is in the enrollee's interest.

AID CONTINUING -- If an enrollee requests a Plan Appeal and then a fair hearing because access to a drug has been reduced or terminated, the enrollee has the right to aid continuing (continued access to the drug in question) while waiting for the Plan Appeal and then the fair hearing. The enrollee must request the Plan Appeal and then the Fair Hearing before the effective date of the IAD and FAD notices, which is a very short time - only 10 days including mailing time. See more about the changes in Managed Care appeals buy propecia finasteride 1mg here. Even though that article is focused on Managed Long Term Care, the new appeals requirements also apply to Mainstream Medicaid managed care. Enrollees who are in the first 90 days of enrollment, or past the first 12 months of enrollment also have the option of switching plans to improve access to their medications.

Consumers who experience problems with access to prescription drugs should always file a complaint with the State Department of Health’s Managed Care buy propecia finasteride 1mg Hotline, number listed below. ACCESSING MEDICAID'S PHARMACY BENEFIT IN FEE FOR SERVICE MEDICAID For those Medicaid recipients who are not yet in a Medicaid Managed Care program, and who do not have Medicare Part D, the Medicaid Pharmacy program covers most of their prescription drugs and select non-prescription drugs and medical supplies for Family Health Plus enrollees. Certain drugs/drug categories require the prescribers to obtain prior authorization. These include brand name drugs buy propecia finasteride 1mg that have a generic alternative under New York's mandatory generic drug program or prescribed drugs that are not on New York's preferred drug list. The full Medicaid formulary can be searched on the eMedNY website.

Even in fee for service Medicaid, prescribers must obtain prior authorization before prescribing non-preferred drugs unless otherwise indicated. Prior authorization is required for original prescriptions, not buy propecia finasteride 1mg refills. A prior authorization is effective for the original dispensing and up to five refills of that prescription within the next six months. Click here for more information on NY's prior authorization process. The New York buy propecia finasteride 1mg State Board of Pharmacy publishes an annual list of the 150 most frequently prescribed drugs, in the most common quantities.

The State Department of Health collects retail price information on these drugs from pharmacies that participate in the Medicaid program. Click here to search for a specific drug from the most frequently prescribed drug list and this site can also provide you with the locations of pharmacies that provide this drug as well as their costs. Click here to view New York State Medicaid’s Pharmacy Provider Manual. WHO YOU CAN CALL FOR HELP Community Health Advocates Hotline. 1-888-614-5400 NY State Department of Health's Managed Care Hotline.

1-800-206-8125 (Mon. - Fri. 8:30 am - 4:30 pm) NY State Department of Insurance.

Propecia prostate pain

Her classes moved Where can i buy antabuse over the counter to Zoom, which propecia prostate pain has made it difficult for her to hear and engage. Right now, Josh is working with her to get noise cancelling headphones to help with her Zoom classes. Local food pantries have limited hours now because of hair loss treatment, so Josh has also picked up food boxes for Cindy when she’s working on school projects.

If it weren’t for Josh, “I would have put propecia prostate pain my education on hold,” said Cindy (we are not using her last name to protect her privacy). Because of the broad scope and flexibility of the program, Josh was able to fill gaps that would have otherwise been outside the purview of many social service agencies or medical organizations that have a more singular focus. “I really have a heart for connecting people to things they need the most,” said Josh.

Building Bridges Across Sectors For the last several years, the Bridges to Health program has connected individuals propecia prostate pain and families to resources in rural Wasco and Hood River counties in Oregon. This year, hair loss treatment has required the program to quickly pivot to support those in quarantine or isolation while continuing to serve clients struggling to access resources on their own. The Columbia Gorge Region, where Wasco and Hood River counties are located, received the Robert Wood Johnson Culture of Health Prize in 2016 largely because of its extensive community engagement and collaboration across sectors.

This means medical providers, propecia prostate pain local government agencies, non-profits, and community members all work together to improve the community’s health. Bridges to Health is a cross-sector program that works to improve access to resources, increase collaboration in and out of the healthcare system, and empower community members to improve their health. Its staff, who are community health workers (also known as CHWs), work closely with clients who might have challenges accessing medical or dental care, housing, food, transportation, and other basic needs.

CHWs are employed by local government agencies and non-profits that contract with the Columbia Gorge Health propecia prostate pain Council, the organization that houses Bridges to Health. Columbia Gorge Health Council staff members serve as the program’s “HUB”, which provides oversight, quality improvement, training, and program evaluation. Clients get referred to Bridges to Health by a medical or social-service provider and then get connected to a CHW.

What makes this program different from other programs is its broad scope and ability to address any issue, from getting into the dentist propecia prostate pain office to new glasses or roof repairs. Bridges to Health focuses on health and social determinants of health. Factors like housing and food access that affect health outcomes.

And, the strong connection propecia prostate pain and trust built between clients and CHWs makes for lasting relationships. According to another Bridges to Health client named Alicia, “Bridges to Health is like a tree. It’s able to branch, flexibly, from one resource to another as it supports its clients.

Stepping Up Support During hair loss treatment Like this story? propecia prostate pain. Sign up for our newsletter. In the spring, when local leaders realized how hair loss treatment would affect the community, the health departments in Hood River and Wasco counties reached out to the Bridges to Health program for support.

€œOn March propecia prostate pain 15th, hair loss treatment hit. By April 15th, we were getting referrals from both public health departments when people needed assistance in isolation and quarantine so that they could stay safely isolated,” said Suzanne Cross, senior program manager with the Columbia Gorge Health Council. The program had to adapt quickly.

Before hair loss treatment, CHWs worked with clients at a slower pace, building trust and assisting with applications propecia prostate pain for programs like the Supplemental Nutrition Assistance Program (SNAP) or Medicaid that often require a wait time for approval. While CHWs have continued to do this work through hair loss treatment, they are also contacting clients in isolation the same day they receive a referral. €œMy coworkers and I are able to provide these families a piece of immediate help,” said Katrina Loikkanen, a CHW based at Mid-Columbia Housing Authority.

€œJust chatting on the phone if they propecia prostate pain need someone to talk to for an hour, we’re here. It could be buying and delivering groceries, which ultimately makes a huge difference in health outcomes. It not only allows clients to remain isolated and limit spread of hair loss treatment, but lets them take care of themselves and their families and put their mental health first.” Still, a stigma around hair loss treatment persists in the region and around the country.

Another fundamental part of CHWs’ daily activity is countering this stigma by meeting their propecia prostate pain clients with empathy, respect, and care. “When we reach out and explain how we can support them during isolation, clients across the board have been so hesitant to even accept the help,” said Karen Shultz, CHW based at non-profit The Next Door. Feelings of fear, embarrassment, and shame often accompany an isolation experience, and in many cases, language barriers and cultural differences make accepting help even harder.

CHWs, who are skilled communicators with big hearts, regularly propecia prostate pain put clients at ease. Recently, Karen assisted a pregnant mother in isolation who did not speak English. She needed to feed her family but had never used a microwave, which was the only cooking implement in her isolation hotel room.

€œWe really had to get creative around how to figure out foods that would work for them,” propecia prostate pain said Karen. While an easy solution would be to purchase pre-made microwavable meals for this family, finding culturally appropriate food for clients is something CHWs prioritize. When the wildfires erupted in the Pacific Northwest this September, 40,000 Oregon residents were displaced, compounding the challenges presented by the propecia.

CHW Annette Lutgens, also based at The Next Door, helped support a couple who propecia prostate pain were isolated due to hair loss treatment and then had to evacuate because of the fires. €œWe were scrambling to get not only groceries, but gasoline [for their RV],” said Annette. After a stressful few weeks, the couple is now off isolation and was able to return to their home.

Many clients in isolation are families with children who are propecia prostate pain also struggling with basic needs like heat, internet, and food security. This reality has made Bridges to Health leadership realize that many families in the community were not getting the services they needed prior to hair loss treatment. Many clients stay enrolled in the program after their isolation period, working with their CHW on longer term goals.

This year propecia prostate pain has not been an easy one, but the program’s cross-sector model, its ability to quickly shift gears, and its resilient staff have allowed it to address the community’s changing needs. Support Our Rural Reporting For the rest of 2020, you have a special opportunity to double your contribution to the Daily Yonder. Your gift will be matched dollar for dollar by NewsMatch, a nonprofit news funding program.

“As our program started receiving isolation referrals, I began to wonder if we could keep up,” said Katy Williams, HUB coordinator for Bridges to Health propecia prostate pain. €œFor anyone who has worked in systems that receive many referrals, you know that same-day response is incredibly difficult. But because of the adaptability, compassion, and perseverance of the CHWs, we make it happen every day.” Judy Bankman is an Oregon-based consultant and freelance writer focusing on issues of public health, health equity, and sustainable food systems.

She received her propecia prostate pain Master of Public Health from New York University’s School of Global Public Health in 2014. You Might Also LikeStart Preamble Office of the Secretary, Department of Health and Human Services. Request for information (RFI).

The U.S propecia prostate pain. Department of Health and Human Services (HHS) seeks to gain a comprehensive understanding of the impact of changes adopted by health care systems and health care providers in response to the hair loss treatment propecia. Many healthcare systems and clinicians have rapidly reengineered their policies and programs to improve access, safety, quality, outcomes including mortality and morbidity, cost, and value for both hair loss treatment and non-hair loss treatment related medical conditions.

HHS plans to identify and learn from effective innovative approaches and best practices implemented by non-HHS organizations in order to inform HHS priorities and programs propecia prostate pain. We recommend that you submit your comments through the Innovation RFI Response Portal (https://rfi.grants.nih.gov/​?. S=​5f89e1e8400f00001a0036f2) to ensure consideration.

Comments must be received through this portal no later than midnight Eastern propecia prostate pain Time (ET) on December 24, 2020. Submissions received after the deadline will not be reviewed. Comments may also be submitted in regulations.gov.

Comments, including mass comment submissions, must be submitted electronically using the Innovation RFI Response Portal propecia prostate pain (https://rfi.grants.nih.gov/​?. S=​5f89e1e8400f00001a0036f2). Please respond concisely, in plain language, and in a narrative format in the field provided for each question, to ensure accurate interpretation and analysis.

You may respond to some or all of the propecia prostate pain topic areas covered in the RFI, and/or you can also provide relevant information that may not have been referenced. You can also include links to online material or interactive presentations. Please do not include any personally identifiable patient information or confidential business information in your comment.

Start Further Info CAPT Meena propecia prostate pain Vythilingam, Director, Center for Health Innovation, Office of the Assistant Secretary for Health, Meena.Vythilingam@HHS.gov or 202 260 7382. End Further Info End Preamble Start Supplemental Information I. Background In response to the 2019 novel hair loss or hair loss treatment propecia, the Secretary of Health and Human Services (HHS) declared a public health emergency effective January 27, 2020, under section 319 of the Public Health Start Printed Page 75022Service Act (42 U.S.C.

247d [] ) and renewed it continually propecia prostate pain since its issuance. The impact of the hair loss treatment propecia on the nation's healthcare system has been complex, widespread, and potentially enduring. This unprecedented propecia has impacted the safety, quality, continuity, outcomes, value, and access to timely health care in numerous healthcare settings.

Anecdotal reports as well as data from varied public sources confirmed that in addition to hair loss treatment-related increases in mortality and morbidity, the mortality and morbidity for numerous non-hair loss treatment-related medical conditions has also increased.[] The hair loss treatment public propecia prostate pain health emergency is disproportionately affecting vulnerable populations, particularly the elderly, and racial and ethnic minorities.[] Local health systems with a significant burden of hair loss treatment cases have faced multiple challenges including surge capacity, staffing, and supply chain issues, that directly impact access, quality, and experience of care for all medical conditions.[] Decreases in help-seeking behaviors in the context of the hair loss treatment propecia may have also contributed to delays in accessing timely care, resulting in poor outcomes.[] In addition to the disruption in healthcare, the delivery of long-term services and supports (LTSS) to many seniors and people with disabilities has also been disrupted during the propecia. In response to the hair loss treatment propecia, medical providers, medical facilities, academic centers, and health systems rapidly reengineered healthcare policies and programs to ensure preservation of health care access, safety, quality, continuity, value, and outcomes. As a result, there has been a proliferation of innovative programs, policies, and best practices to prevent and mitigate the consequences of hair loss treatment, while simultaneously preserving access to routine and emergency healthcare services for non-hair loss treatment medical conditions.[] An example of the paradigmatic shift in the delivery of health care is the rapid adoption and scaling of telehealth services.[] Although the propecia disrupted the entire health care ecosystem in the U.S., it also provided an opportunity and impetus to innovate across the continuum of individual and population health, including screening, surveillance, prevention, treatment, supply chain management, and public health interventions.

These changes may persist for the propecia prostate pain duration of the public health emergency, and potentially beyond it. HHS strongly supports innovation to preserve a resilient healthcare system in the face of the hair loss treatment propecia and recognizes the importance of learning from effective and innovative approaches and best practices implemented by non-HHS healthcare systems, academic centers, and healthcare providers. HHS will determine if these innovative approaches and best practices can help inform and/or improve HHS priorities and programs.

II. Scope and Assumptions The main purpose of this Request for Information (RFI) is for HHS to gather information on effective innovative approaches and best practices in health care in response to the hair loss treatment propecia by non-HHS health care systems and providers. The information provided will help inform and guide the HHS response to build a healthy and resilient nation.

This RFI includes innovations and best practices in health care for both hair loss treatment and non-hair loss treatment health conditions. The definition of “health” system or services and/or “healthcare” system or services, for the purposes of this RFI, is broad. We seek an understanding of effective best practices and innovations in the provision of services across the health and public health continuum by a variety of organizations.

Responses can focus on select aspects or on the entire continuum of care, to include surveillance, screening, prevention, treatment, and/or public health interventions. We are specifically interested in novel approaches and best practices that are associated with data confirming efficacy and/or effectiveness with demonstrated improvements in one or more of the following measures. Patient outcomes, access to health care, safety, quality, and/or value.

Responses should include the following. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy. And results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study.

○ Costs associated with implementing the the innovation/best practice. ○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?.

○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?. If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?.

(If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively). ○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively).

III. Information Requested/Key Questions Please respond to specific topics in which you have the most amount of evidence and expertise. Respondents are requested to share the objective results of an evaluation for each topic when possible.

Response to every item is not required. A. Health Promotion and Prevention of hair loss treatment and Non-hair loss treatment Medical Conditions Please provide the following information.

—‹ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice. Start Printed Page 75023 ○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data.

Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.). Analytic strategy.

And results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe effective innovations/best practices that prevented the transmission of hair loss s in staff, patients and/or beneficiaries. 2. Describe effective innovations/best practices to prevent hair loss outbreaks among residents and staff in long-term care facilities including assisted living facilities, nursing homes, rehabilitation facilities, intermediate care facilities for individuals with intellectual disabilities (ICF/ID), and palliative care settings.

3. Describe innovative programs/policies and best practices to ensure timely access to health care and continuity of care for patients with chronic illnesses that increase vulnerability to hair loss treatment. 4.

Provide details on innovations or best practices that prevented increases in morbidity and mortality due to deferred care for acute medical conditions (e.g., cardiac arrests, strokes, etc.). 5. Describe effective programs or practices that helped ensure timely administration of immunizations to pediatric patients and other vulnerable populations including the elderly and individuals with disabilities.

6. Elaborate on effective educational and messaging campaigns targeting prevention. 7.

Describe effective health promotion and prevention policies and programs implemented in response to hair loss treatment, that will continue beyond this propecia. B. Screening/Surveillance/Case Identification of hair loss treatment and Non-hair loss treatment Medical Conditions Please provide the following information.

○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice. ○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data.

Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.). Analytic strategy, and results.

If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice. ○ Have these innovations/best practices been incorporated as permanent organizational changes?.

If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?. If yes, please describe the potential impacts on outcomes.

○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively). ○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?.

(If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1. Describe effective approaches to screening, surveillance and case identification of hair loss treatment.

2. Describe efforts to ensure that patients continue to receive United States Preventive Services Task Force-recommended screening procedures on time during the hair loss treatment propecia. Please include data on the program's ability to prevent negative outcomes due to timely screening and early detection, if available.

3. Outline innovative programs to continue screening for HIV, hepatitis and sexually transmitted diseases during the propecia, (e.g., in syringe services programs (SSPs)). C.

Treatment for hair loss treatment and Non-hair loss treatment Medical Conditions Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe innovations/best practices in hair loss treatment that resulted in decreased mortality and morbidity. 2. Describe if and how a health care system was effectively reengineered to ensure timely access and quality of care in the Emergency Department, Outpatient or Inpatient settings.

3. Describe how appropriate utilization of emergency medical services was facilitated during the propecia. 4.

Detail effective changes in intensive care unit (ICU) care and post-hospital care/follow-up. 5. Detail best practices to ensure continuity of treatment for HIV, hepatitis and sexually transmitted diseases during the propecia.Start Printed Page 75024 6.

Describe effective programs/policies to prevent/manage dental emergencies during the propecia. 7. Outline novel and effective approaches to ensure compliance with medications, including refills, during the propecia.

8. Please list effective treatment-related policies or programs that will continue beyond the hair loss treatment propecia. D.

Telehealth Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe effective best practices to deliver clinical and nonclinical services using telehealth (e.g., surveillance, prevention and treatment services, etc). 2. Describe best practices and innovations to improve access to care for rural/remote populations using telehealth, during the propecia.

3. Detail effective use of remote monitoring/telemonitoring of chronic medical conditions including diabetes and hypertension and for delivering home health services. 4.

List criticial barriers to implement telehealth in healthcare systems. 5. What are some of the key facilitators of telehealth?.

6. Outline innovative approaches to integrate telehealth into the clinical work flow. 7.

List effective telehealth programs that will continue beyond this propecia. 8. Describe technological systems that facilitate telehealth, including use of audio or video telehealth, telehealth programs or apps, or other approaches.

9. Describe technological systems that might or might not facilitate telehealth, including uses of audio or video telehealth, telehealth programs or apps, or other approaches. E.

Mental Health/Behavioral Health and Substance Use Disorder Innovations/Best Practices Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe effective, novel mental health prevention and/or treatment programs in response to the hair loss treatment propecia. 2. Describe effective and innovative substance use disorder programs during the hair loss treatment propecia.

3. Describe innovative efforts to provide medication-assisted treatment, including access to counseling and support groups, during the propecia. 4.

Provide information on effective suicide prevention programs implemented during the propecia. 5. Provide information on effective programs designed to identify childhood abuse, elder abuse and/or domestic violence during the propecia.

6. Detail effective approaches to prevent hair loss treatment transmission in psychiatric and substance use disorder residential and group treatment facilities. F.

Population-Level Interventions Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe innovations/best practices in preventing and/or treating hair loss treatment in high risk and vulnerable populations including but not limited to, African-Americans, Asian Americans, Start Printed Page 75025Hispanics/Latinos, American Indians/Alaska Natives, persons with disabilities, persons with limited English proficiency and others who might have been disproportionately impacted by hair loss treatment, directly or because treatment for other medical conditions has been disrupted. 2. Provide details on effective, community-based, innovative programs to improve population health during the hair loss treatment propecia (e.g., programs to address social determinants of health).

3. Outline effective and innovative approaches to address health disparities across the continuum of care during the hair loss treatment propecia. 4.

Detail effective approaches to address social isolation in vulnerable populations including older-adults and people with disabilities in both institutional and community settings. G. Other Topics 1.

Please describe effective strategies to address other critical barriers, including work force concerns, provider well-being, supply chain, etc., to ensure continuity of operations in a healthcare system. 2. Outline best practices to ensure seamless delivery of long-term services and supports (LTSS) to residents of group homes for individuals with disabilities, and other recipients of home-and-community-based services during the propecia.

3. Detail new programs/policies and efforts that were implemented during the propecia, but found to be ineffective in improving healthcare access, safety, quality, continuity, value and outcomes. 4.

Please describe other input not already covered by the previous topics. HHS encourages all potentially interested parties including individuals, healthcare providers, networks and/or associations, academic researchers and institutions, non-HHS federal healthcare systems, non-governmental organizations, and private sector entities to respond. IV.

How To Submit Your Response Please upload your responses to each question in this Innovation RFI response tool which has clearly marked sections for individual questions. Please respond concisely, in plain language, and in narrative format. You may respond to some or all of the questions listed in the RFI.

Please ensure it is clear which question you are responding to. You may also include links to online material or interactive presentations. Please note that this is a request for information (RFI) only.

In accordance with the implementing regulations of the Paperwork Reduction Act of 1995 (PRA), specifically 5 CFR 1320.3(h) (4), this general solicitation is exempt from the PRA. Facts or opinions submitted in response to general solicitations of comments from the public, published in the Federal Register or other publications, regardless of the form or format thereof, provided that no person is required to supply specific information pertaining to the commenter, other than that necessary for self-identification, as a condition of the agency's full consideration, are not generally considered information collections and therefore not subject to the PRA. This RFI is issued solely for information and planning purposes.

It does not constitute a Request for Proposal (RFP), applications, proposal abstracts, or quotations. This RFI does not commit the U.S. Government to contract for any supplies or services or make a grant award.

Further, we are not seeking proposals through this RFI and will not accept unsolicited proposals. We note that not responding to this RFI does not preclude participation in any future procurement, if conducted. It is the responsibility of the potential responders to monitor this RFI announcement for additional information pertaining to this request.

HHS may or may not choose to contact individual responders. Such communications would be for the sole purpose of clarifying statements in written responses. Contractor support personnel may be used to review responses to this RFI.

Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract or issue a grant.

She was connected with Community Health Worker Josh Sendejas, who helped her find an apartment through the housing choice voucher buy propecia finasteride 1mg program. Josh also helped her access what she needed to stay in school, like gas for her car and printer ink for research papers. When hair loss treatment arrived in Cindy’s community in the Columbia River Gorge, she faced new challenges.

Her classes moved to Zoom, which has made it difficult for her to hear buy propecia finasteride 1mg and engage. Right now, Josh is working with her to get noise cancelling headphones to help with her Zoom classes. Local food pantries have limited hours now because of hair loss treatment, so Josh has also picked up food boxes for Cindy when she’s working on school projects.

If it weren’t for Josh, “I would have put buy propecia finasteride 1mg my education on hold,” said Cindy (we are not using her last name to protect her privacy). Because of the broad scope and flexibility of the program, Josh was able to fill gaps that would have otherwise been outside the purview of many social service agencies or medical organizations that have a more singular focus. “I really have a heart for connecting people to things they need the most,” said Josh.

Building Bridges Across Sectors For the last several years, the Bridges to Health program has connected individuals and families to resources buy propecia finasteride 1mg in rural Wasco and Hood River counties in Oregon. This year, hair loss treatment has required the program to quickly pivot to support those in quarantine or isolation while continuing to serve clients struggling to access resources on their own. The Columbia Gorge Region, where Wasco and Hood River counties are located, received the Robert Wood Johnson Culture of Health Prize in 2016 largely because of its extensive community engagement and collaboration across sectors.

This means medical providers, local government agencies, buy propecia finasteride 1mg non-profits, and community members all work together to improve the community’s health. Bridges to Health is a cross-sector program that works to improve access to resources, increase collaboration in and out of the healthcare system, and empower community members to improve their health. Its staff, who are community health workers (also known as CHWs), work closely with clients who might have challenges accessing medical or dental care, housing, food, transportation, and other basic needs.

CHWs are employed by local government agencies and buy propecia finasteride 1mg non-profits that contract with the Columbia Gorge Health Council, the organization that houses Bridges to Health. Columbia Gorge Health Council staff members serve as the program’s “HUB”, which provides oversight, quality improvement, training, and program evaluation. Clients get referred to Bridges to Health by a medical or social-service provider and then get connected to a CHW.

What makes this program different from other programs is its broad scope and buy propecia finasteride 1mg ability to address any issue, from getting into the dentist office to new glasses or roof repairs. Bridges to Health focuses on health and social determinants of health. Factors like housing and food access that affect health outcomes.

And, the buy propecia finasteride 1mg strong connection and trust built between clients and CHWs makes for lasting relationships. According to another Bridges to Health client named Alicia, “Bridges to Health is like a tree. It’s able to branch, flexibly, from one resource to another as it supports its clients.

Stepping Up Support During hair loss treatment Like this buy propecia finasteride 1mg story?. Sign up for our newsletter. In the spring, when local leaders realized how hair loss treatment would affect the community, the health departments in Hood River and Wasco counties reached out to the Bridges to Health program for support.

€œOn March 15th, hair loss treatment hit buy propecia finasteride 1mg. By April 15th, we were getting referrals from both public health departments when people needed assistance in isolation and quarantine so that they could stay safely isolated,” said Suzanne Cross, senior program manager with the Columbia Gorge Health Council. The program had to adapt quickly.

Before hair loss treatment, CHWs worked with clients at a slower pace, building trust and assisting with applications for programs like the Supplemental buy propecia finasteride 1mg Nutrition Assistance Program (SNAP) or Medicaid that often require a wait time for approval. While CHWs have continued to do this work through hair loss treatment, they are also contacting clients in isolation the same day they receive a referral. €œMy coworkers and I are able to provide these families a piece of immediate help,” said Katrina Loikkanen, a CHW based at Mid-Columbia Housing Authority.

€œJust chatting on the phone if they need someone to talk to for an hour, buy propecia finasteride 1mg we’re here. It could be buying and delivering groceries, which ultimately makes a huge difference in health outcomes. It not only allows clients to remain isolated and limit spread of hair loss treatment, but lets them take care of themselves and their families and put their mental health first.” Still, a stigma around hair loss treatment persists in the region and around the country.

Another fundamental part of CHWs’ buy propecia finasteride 1mg daily activity is countering this stigma by meeting their clients with empathy, respect, and care. “When we reach out and explain how we can support them during isolation, clients across the board have been so hesitant to even accept the help,” said Karen Shultz, CHW based at non-profit The Next Door. Feelings of fear, embarrassment, and shame often accompany an isolation experience, and in many cases, language barriers and cultural differences make accepting help even harder.

CHWs, who are skilled communicators with big hearts, buy propecia finasteride 1mg regularly put clients at ease. Recently, Karen assisted a pregnant mother in isolation who did not speak English. She needed to feed her family but had never used a microwave, which was the only cooking implement in her isolation hotel room.

€œWe really buy propecia finasteride 1mg had to get creative around how to figure out foods that would work for them,” said Karen. While an easy solution would be to purchase pre-made microwavable meals for this family, finding culturally appropriate food for clients is something CHWs prioritize. When the wildfires erupted in the Pacific Northwest this September, 40,000 Oregon residents were displaced, compounding the challenges presented by the propecia.

CHW Annette Lutgens, also based at The Next Door, helped support a couple who were isolated due to buy propecia finasteride 1mg hair loss treatment and then had to evacuate because of the fires. €œWe were scrambling to get not only groceries, but gasoline [for their RV],” said Annette. After a stressful few weeks, the couple is now off isolation and was able to return to their home.

Many clients in isolation are families with children who are also struggling with buy propecia finasteride 1mg basic needs like heat, internet, and food security. This reality has made Bridges to Health leadership realize that many families in the community were not getting the services they needed prior to hair loss treatment. Many clients stay enrolled in the program after their isolation period, working with their CHW on longer term goals.

This year has not been an easy one, but the program’s cross-sector model, its ability to quickly shift gears, and its resilient staff have allowed it to buy propecia finasteride 1mg address the community’s changing needs. Support Our Rural Reporting For the rest of 2020, you have a special opportunity to double your contribution to the Daily Yonder. Your gift will be matched dollar for dollar by NewsMatch, a nonprofit news funding program.

“As our program started receiving isolation referrals, I buy propecia finasteride 1mg began to wonder if we could keep up,” said Katy Williams, HUB coordinator for Bridges to Health. €œFor anyone who has worked in systems that receive many referrals, you know that same-day response is incredibly difficult. But because of the adaptability, compassion, and perseverance of the CHWs, we make it happen every day.” Judy Bankman is an Oregon-based consultant and freelance writer focusing on issues of public health, health equity, and sustainable food systems.

She received her Master of Public Health from New York buy propecia finasteride 1mg University’s School of Global Public Health in 2014. You Might Also LikeStart Preamble Office of the Secretary, Department of Health and Human Services. Request for information (RFI).

The U.S buy propecia finasteride 1mg. Department of Health and Human Services (HHS) seeks to gain a comprehensive understanding of the impact of changes adopted by health care systems and health care providers in response to the hair loss treatment propecia. Many healthcare systems and clinicians have rapidly reengineered their policies and programs to improve access, safety, quality, outcomes including mortality and morbidity, cost, and value for both hair loss treatment and non-hair loss treatment related medical conditions.

HHS plans to identify and learn from effective innovative approaches and best practices implemented by non-HHS organizations in order to inform buy propecia finasteride 1mg HHS priorities and programs. We recommend that you submit your comments through the Innovation RFI Response Portal (https://rfi.grants.nih.gov/​?. S=​5f89e1e8400f00001a0036f2) to ensure consideration.

Comments must be buy propecia finasteride 1mg received through this portal no later than midnight Eastern Time (ET) on December 24, 2020. Submissions received after the deadline will not be reviewed. Comments may also be submitted in regulations.gov.

Comments, including mass comment submissions, must buy propecia finasteride 1mg be submitted electronically using the Innovation RFI Response Portal (https://rfi.grants.nih.gov/​?. S=​5f89e1e8400f00001a0036f2). Please respond concisely, in plain language, and in a narrative format in the field provided for each question, to ensure accurate interpretation and analysis.

You may respond to some or all buy propecia finasteride 1mg of the topic areas covered in the RFI, and/or you can also provide relevant information that may not have been referenced. You can also include links to online material or interactive presentations. Please do not include any personally identifiable patient information or confidential business information in your comment.

Start Further buy propecia finasteride 1mg Info CAPT Meena Vythilingam, Director, Center for Health Innovation, Office of the Assistant Secretary for Health, Meena.Vythilingam@HHS.gov or 202 260 7382. End Further Info End Preamble Start Supplemental Information I. Background In response to the 2019 novel hair loss or hair loss treatment propecia, the Secretary of Health and Human Services (HHS) declared a public health emergency effective January 27, 2020, under section 319 of the Public Health Start Printed Page 75022Service Act (42 U.S.C.

247d [] ) and buy propecia finasteride 1mg renewed it continually since its issuance. The impact of the hair loss treatment propecia on the nation's healthcare system has been complex, widespread, and potentially enduring. This unprecedented propecia has impacted the safety, quality, continuity, outcomes, value, and access to timely health care in numerous healthcare settings.

Anecdotal reports as well as data from varied public sources confirmed that in addition to hair loss treatment-related increases in mortality and morbidity, the mortality and morbidity for numerous non-hair loss treatment-related medical conditions has also increased.[] The hair loss treatment public health emergency is disproportionately affecting vulnerable populations, particularly the elderly, and racial and ethnic minorities.[] Local health systems with a significant burden of hair loss treatment cases have faced multiple challenges including surge capacity, staffing, and supply chain issues, that directly impact access, quality, and experience of care for all medical conditions.[] Decreases in help-seeking behaviors in the context of the hair loss treatment propecia may have also contributed to delays in accessing timely care, resulting in poor outcomes.[] In addition buy propecia finasteride 1mg to the disruption in healthcare, the delivery of long-term services and supports (LTSS) to many seniors and people with disabilities has also been disrupted during the propecia. In response to the hair loss treatment propecia, medical providers, medical facilities, academic centers, and health systems rapidly reengineered healthcare policies and programs to ensure preservation of health care access, safety, quality, continuity, value, and outcomes. As a result, there has been a proliferation of innovative programs, policies, and best practices to prevent and mitigate the consequences of hair loss treatment, while simultaneously preserving access to routine and emergency healthcare services for non-hair loss treatment medical conditions.[] An example of the paradigmatic shift in the delivery of health care is the rapid adoption and scaling of telehealth services.[] Although the propecia disrupted the entire health care ecosystem in the U.S., it also provided an opportunity and impetus to innovate across the continuum of individual and population health, including screening, surveillance, prevention, treatment, supply chain management, and public health interventions.

These changes may persist for the duration of the public health emergency, and potentially beyond buy propecia finasteride 1mg it. HHS strongly supports innovation to preserve a resilient healthcare system in the face of the hair loss treatment propecia and recognizes the importance of learning from effective and innovative approaches and best practices implemented by non-HHS healthcare systems, academic centers, and healthcare providers. HHS will determine if these innovative approaches and best practices can help inform and/or improve HHS priorities and programs.

II. Scope and Assumptions The main purpose of this Request for Information (RFI) is for HHS to gather information on effective innovative approaches and best practices in health care in response to the hair loss treatment propecia by non-HHS health care systems and providers. The information provided will help inform and guide the HHS response to build a healthy and resilient nation.

This RFI includes innovations and best practices in health care for both hair loss treatment and non-hair loss treatment health conditions. The definition of “health” system or services and/or “healthcare” system or services, for the purposes of this RFI, is broad. We seek an understanding of effective best practices and innovations in the provision of services across the health and public health continuum by a variety of organizations.

Responses can focus on select aspects or on the entire continuum of care, to include surveillance, screening, prevention, treatment, and/or public health interventions. We are specifically interested in novel approaches and best practices that are associated with data confirming efficacy and/or effectiveness with demonstrated improvements in one or more of the following measures. Patient outcomes, access to health care, safety, quality, and/or value.

Responses should include the following. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy. And results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study.

○ Costs associated with implementing the the innovation/best practice. ○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?.

○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?. If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?.

(If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively). ○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively).

III. Information Requested/Key Questions Please respond to specific topics in which you have the most amount of evidence and expertise. Respondents are requested to share the objective results of an evaluation for each topic when possible.

Response to every item is not required. A. Health Promotion and Prevention of hair loss treatment and Non-hair loss treatment Medical Conditions Please provide the following information.

—‹ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice. Start Printed Page 75023 ○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data.

Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.). Analytic strategy.

And results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe effective innovations/best practices that prevented the transmission of hair loss s in staff, patients and/or beneficiaries. 2. Describe effective innovations/best practices to prevent hair loss outbreaks among residents and staff in long-term care facilities including assisted living facilities, nursing homes, rehabilitation facilities, intermediate care facilities for individuals with intellectual disabilities (ICF/ID), and palliative care settings.

3. Describe innovative programs/policies and best practices to ensure timely access to health care and continuity of care for patients with chronic illnesses that increase vulnerability to hair loss treatment. 4.

Provide details on innovations or best practices that prevented increases in morbidity and mortality due to deferred care for acute medical conditions (e.g., cardiac arrests, strokes, etc.). 5. Describe effective programs or practices that helped ensure timely administration of immunizations to pediatric patients and other vulnerable populations including the elderly and individuals with disabilities.

6. Elaborate on effective educational and messaging campaigns targeting prevention. 7.

Describe effective health promotion and prevention policies and programs implemented in response to hair loss treatment, that will continue beyond this propecia. B. Screening/Surveillance/Case Identification of hair loss treatment and Non-hair loss treatment Medical Conditions Please provide the following information.

○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice. ○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data.

Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.). Analytic strategy, and results.

If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice. ○ Have these innovations/best practices been incorporated as permanent organizational changes?.

If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?. If yes, please describe the potential impacts on outcomes.

○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively). ○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?.

(If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1. Describe effective approaches to screening, surveillance and case identification of hair loss treatment.

2. Describe efforts to ensure that patients continue to receive United States Preventive Services Task Force-recommended screening procedures on time during the hair loss treatment propecia. Please include data on the program's ability to prevent negative outcomes due to timely screening and early detection, if available.

3. Outline innovative programs to continue screening for HIV, hepatitis and sexually transmitted diseases during the propecia, (e.g., in syringe services programs (SSPs)). C.

Treatment for hair loss treatment and Non-hair loss treatment Medical Conditions Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe innovations/best practices in hair loss treatment that resulted in decreased mortality and morbidity. 2. Describe if and how a health care system was effectively reengineered to ensure timely access and quality of care in the Emergency Department, Outpatient or Inpatient settings.

3. Describe how appropriate utilization of emergency medical services was facilitated during the propecia. 4.

Detail effective changes in intensive care unit (ICU) care and post-hospital care/follow-up. 5. Detail best practices to ensure continuity of treatment for HIV, hepatitis and sexually transmitted diseases during the propecia.Start Printed Page 75024 6.

Describe effective programs/policies to prevent/manage dental emergencies during the propecia. 7. Outline novel and effective approaches to ensure compliance with medications, including refills, during the propecia.

8. Please list effective treatment-related policies or programs that will continue beyond the hair loss treatment propecia. D.

Telehealth Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe effective best practices to deliver clinical and nonclinical services using telehealth (e.g., surveillance, prevention and treatment services, etc). 2. Describe best practices and innovations to improve access to care for rural/remote populations using telehealth, during the propecia.

3. Detail effective use of remote monitoring/telemonitoring of chronic medical conditions including diabetes and hypertension and for delivering home health services. 4.

List criticial barriers to implement telehealth in healthcare systems. 5. What are some of the key facilitators of telehealth?.

6. Outline innovative approaches to integrate telehealth into the clinical work flow. 7.

List effective telehealth programs that will continue beyond this propecia. 8. Describe technological systems that facilitate telehealth, including use of audio or video telehealth, telehealth programs or apps, or other approaches.

9. Describe technological systems that might or might not facilitate telehealth, including uses of audio or video telehealth, telehealth programs or apps, or other approaches. E.

Mental Health/Behavioral Health and Substance Use Disorder Innovations/Best Practices Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe effective, novel mental health prevention and/or treatment programs in response to the hair loss treatment propecia. 2. Describe effective and innovative substance use disorder programs during the hair loss treatment propecia.

3. Describe innovative efforts to provide medication-assisted treatment, including access to counseling and support groups, during the propecia. 4.

Provide information on effective suicide prevention programs implemented during the propecia. 5. Provide information on effective programs designed to identify childhood abuse, elder abuse and/or domestic violence during the propecia.

6. Detail effective approaches to prevent hair loss treatment transmission in psychiatric and substance use disorder residential and group treatment facilities. F.

Population-Level Interventions Please provide the following information. ○ A description of the innovation/best practice. ○ The rationale for the implementation of the innovation/best practice.

○ Data and/or results confirming efficacy and/or effectiveness of the innovation/best practice, including demographic data. Control conditions. Outcomes measures (e.g., mortality, morbidity, health care access, safety, quality, cost, value, etc.).

Analytic strategy, and results. If the evaluation is currently underway, please describe the study design and expected timeline for completion of the study. ○ Costs associated with implementing the the innovation/best practice.

○ Have these innovations/best practices been incorporated as permanent organizational changes?. If not, why not?. ○ Can the innovation/best practice be scaled to larger, diverse groups and/or locations for a longer period?.

If yes, please describe the potential impacts on outcomes. ○ Did or could specific HHS policies or programs facilitate the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice positively).

○ By contrast, did or could specific HHS policies or programs hinder the design and implementation of an innovation/best practice?. (If yes, please provide details of how the policy or program affects or could affect the innovation/best practice negatively). 1.

Describe innovations/best practices in preventing and/or treating hair loss treatment in high risk and vulnerable populations including but not limited to, African-Americans, Asian Americans, Start Printed Page 75025Hispanics/Latinos, American Indians/Alaska Natives, persons with disabilities, persons with limited English proficiency and others who might have been disproportionately impacted by hair loss treatment, directly or because treatment for other medical conditions has been disrupted. 2. Provide details on effective, community-based, innovative programs to improve population health during the hair loss treatment propecia (e.g., programs to address social determinants of health).

3. Outline effective and innovative approaches to address health disparities across the continuum of care during the hair loss treatment propecia. 4.

Detail effective approaches to address social isolation in vulnerable populations including older-adults and people with disabilities in both institutional and community settings. G. Other Topics 1.

Please describe effective strategies to address other critical barriers, including work force concerns, provider well-being, supply chain, etc., to ensure continuity of operations in a healthcare system. 2. Outline best practices to ensure seamless delivery of long-term services and supports (LTSS) to residents of group homes for individuals with disabilities, and other recipients of home-and-community-based services during the propecia.

3. Detail new programs/policies and efforts that were implemented during the propecia, but found to be ineffective in improving healthcare access, safety, quality, continuity, value and outcomes. 4.

Please describe other input not already covered by the previous topics. HHS encourages all potentially interested parties including individuals, healthcare providers, networks and/or associations, academic researchers and institutions, non-HHS federal healthcare systems, non-governmental organizations, and private sector entities to respond. IV.

How To Submit Your Response Please upload your responses to each question in this Innovation RFI response tool which has clearly marked sections for individual questions. Please respond concisely, in plain language, and in narrative format. You may respond to some or all of the questions listed in the RFI.

Please ensure it is clear which question you are responding to. You may also include links to online material or interactive presentations. Please note that this is a request for information (RFI) only.

In accordance with the implementing regulations of the Paperwork Reduction Act of 1995 (PRA), specifically 5 CFR 1320.3(h) (4), this general solicitation is exempt from the PRA. Facts or opinions submitted in response to general solicitations of comments from the public, published in the Federal Register or other publications, regardless of the form or format thereof, provided that no person is required to supply specific information pertaining to the commenter, other than that necessary for self-identification, as a condition of the agency's full consideration, are not generally considered information collections and therefore not subject to the PRA. This RFI is issued solely for information and planning purposes.

It does not constitute a Request for Proposal (RFP), applications, proposal abstracts, or quotations. This RFI does not commit the U.S. Government to contract for any supplies or services or make a grant award.

Further, we are not seeking proposals through this RFI and will not accept unsolicited proposals. We note that not responding to this RFI does not preclude participation in any future procurement, if conducted. It is the responsibility of the potential responders to monitor this RFI announcement for additional information pertaining to this request.

HHS may or may not choose to contact individual responders.

;